Orchid Pharma Limited — Investor Meet, 14-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Orchid Pharma's Q1 FY26 sales hit INR173 Cr, down 29% year-on-year, with operational EBITDA at INR14 Cr. Despite a tough antibiotic market and price pressure, gross margins stayed at 42%. A major strategic win: Orchid acquired global rights to Enmetazobactam (Exblifep) from Allecra, securing all future royalties. US market entry for Exblifep is a priority. Domestic brand Orblicef is stable. The 7ACA project is on track for Q1 FY27, and Cefiderocol for Dec 2026. Management foresees a muted FY26 but is confident in navigating challenges and foresees market recovery.